Humanigen announced it has entered into an arrangement with Clinigen to implement a Managed Access Program for lenzilumab (“LenzMAP™”).
LenzMAP will enable access to lenzilumab on a case-by-case basis for hospitalized patients with COVID-19 where the treating physician deems there to be no suitable alternatives and where regulations allow. LenzMAP will be available in the following 16 European countries: Austria, Bulgaria, Croatia, Cyprus, Denmark, Estonia, France, Greece, Ireland, Lithuania, Luxembourg, Netherlands, Portugal, Spain, Sweden, and Switzerland. To date there have been over 20 million cases of COVID-19 reported in these countries.1 Lenzilumab is an investigational product and is not currently authorized or approved in any country.
“We are working with Clinigen to provide access to lenzilumab on a patient-by-patient basis in specific European countries,” said Timothy E. Morris, COO and CFO of Humanigen. “While we continue to pursue a Marketing Authorization Application for lenzilumab and await the associated review by the European Medicines Agency, as well as a decision regarding conditional marketing authorization, the Managed Access Program will enable Humanigen to respond positively to requests for access from healthcare professionals to treat hospitalized patients where allowed by the local regulatory authorities. We look forward to working with Clinigen.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!